Light, ex-vivo treatment and antivirals for lungs from hepatitis B donors
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests a new way to safely use donor lungs that carry the hepatitis B virus (HBV). It combines a special light treatment, ex-vivo lung perfusion (cleaning the lungs outside the body), and antiviral medicines to prevent infection in the recipient. If you are on the lung transplant list and have been vaccinated against hepatitis B, this study may help expand your donor options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already listed for a lung transplant.
- You do not have active hepatitis B infection (your NAT test is negative).
- You have had at least 3 hepatitis B vaccines or have a protective antibody level (anti-HBs >=10 IU/mL).
- You do not have significant liver damage (more than mild scarring).
- You are not already infected with hepatitis B (negative for HBsAg and core antibody).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching from the regular entecavir pill to a new orally dissolving version works just as well and is safe for patients who have had a liver transplant due to hepatitis B. If you've been stable on entecavir, this could be a convenient alternative.
This study tests whether it's safe and effective for people with HIV to receive a liver transplant from a donor who also has HIV. It aims to expand access to transplants for people with HIV.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This study tests whether giving people with HIV a liver from an HIV-positive donor is safe and works well. It looks at infections, cancer risks, and long-term health after transplant.
This trial tests whether adding a special filtering treatment (hemodiafiltration) during the lung reconditioning process (EVLP) can help improve marginal donor lungs before transplant. It aims to see if more lungs can be used for patients waiting for a transplant.
Hear when a new Lung Transplant Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.